Literature DB >> 16714709

Pathobiology of idiopathic ascending aortic aneurysms.

E W Matthias Kirsch1, N Costin Radu, Eric Allaire, Daniel Y Loisance.   

Abstract

The majority of ascending aortic aneurysms cannot be related to any specific etiology and should be qualified as idiopathic. The pathobiology of ascending aortic aneurysms remains incompletely understood. Data from direct study are still scarce and often limited because of patient heterogenicity. Currently available information suggests that destructive remodeling of the aortic wall, inflammation and angiogenesis, biomechanical wall stress, and molecular genetics are relevant mechanisms of idiopathic ascending aortic aneurysm formation and progression. Further understanding of these mechanisms will likely provide novel diagnostic, prognostic, and therapeutical tools for the clinician.

Entities:  

Mesh:

Year:  2006        PMID: 16714709     DOI: 10.1177/021849230601400320

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  3 in total

1.  In vivo three-dimensional MR wall shear stress estimation in ascending aortic dilatation.

Authors:  Erik T Bieging; Alex Frydrychowicz; Andrew Wentland; Benjamin R Landgraf; Kevin M Johnson; Oliver Wieben; Christopher J François
Journal:  J Magn Reson Imaging       Date:  2011-03       Impact factor: 4.813

2.  Metabolomic profiling of ascending thoracic aortic aneurysms and dissections - Implications for pathophysiology and biomarker discovery.

Authors:  Christian Doppler; Kathrin Arnhard; Julia Dumfarth; Katharina Heinz; Barbara Messner; Christian Stern; Therese Koal; Kristaps Klavins; Katarina Danzl; Florian Pitterl; Michael Grimm; Herbert Oberacher; David Bernhard
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

3.  Bicuspid valve aortopathy is associated with distinct patterns of matrix degradation.

Authors:  Ya Hua Chim; Hannah A Davies; David Mason; Omar Nawaytou; Mark Field; Jillian Madine; Riaz Akhtar
Journal:  J Thorac Cardiovasc Surg       Date:  2019-09-25       Impact factor: 5.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.